GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The candidate has been approved under the brand name Attruby. BBIO stock surged 16.1% on the FDA approval of the drug. BridgeBio’s shares have lost 32.6% in the year-to-date period against the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO)的口服药物Attruby™ (acoramidis)获得美国食品和药物管理局 (FDA)批准，用于治疗成年ATTR-CM患者，旨在降低心血管死亡和住院率。这一批准是基于ATTRibute-CM第3期研究的积极结果。受此消息影响，BridgeBio股价上涨25%。

On Monday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $22.35 which represents a decrease of $-1.37 or -5.78% from the prior close of $23.72. The stock opened at $23.32 and ...